NEUROCRINE BIOSCIENCES INC (NBIX) Stock Price, Financials & Summary

Price chart

Sep 24Sep 29Oct 2Oct 7Oct 12Oct 15Oct 20Oct 23

Key dataOct 23, 2026

Open$143.52

From 52W high−23.07%

Volume1.03M

Market cap$14.51B

P/E (TTM)20.2x

P/S (TTM)4.3x

Div yield—

Key dataOct 23, 2026

Open

$143.52

From 52W high

−23.07%

Volume

1.03M

Market cap

$14.51B

ValuationView details →

P/E (Fwd)

15.8x

EV/EBITDA

15.8x

P/E (TTM)

20.2x

RSI (14)

48.6

MomentumView details →

1D Return

−0.41%

YTD Return

+0.20%

SummaryUpdated Jun 1, 2026

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a San Diego-based biopharmaceutical company founded in 1992 and publicly traded since 1996. The company specializes in developing and commercializing treatments for neurological, endocrine, and psychiatric disorders. Originally focused on research and development, Neurocrine has evolved into a commercial-stage company with multiple marketed products and a robust pipeline of investigational therapies. The company has established itself as a leader in movement disorders and rare diseases, with its flagship product INGREZZA becoming a blockbuster treatment for tardive dyskinesia.

Ask drillr about NEUROCRINE BIOSCIENCES INC →

ValuationView details →

P/E (Fwd)

15.8x

P/E (TTM)

20.2x

EV/EBITDA

15.8x

EV/Sales

4.3x

P/S (TTM)

4.3x

P/B (TTM)

3.9x

ProfitabilityView details →

Gross Margin

97.97%

Net Margin

20.91%

EBITDA Margin

27.21%

ROE (TTM)

19.10%

ROA (TTM)

13.16%

Asset Turnover

0.66x

GrowthView details →

Revenue YoY

+34.42%

EPS YoY

+102.59%

FCF YoY

+64.63%

Revenue CAGR 3Y

+24.32%

EPS CAGR 3Y

+44.03%

EBITDA YoY

+60.76%

MomentumView details →

1D Return

−0.41%

YTD Return

+0.20%

1Y Return

−1.31%

RSI (14)

48.6

vs 50D SMA

−3.60%

vs 200D SMA

−3.38%

Capital & dividendView details →

Debt/Equity

0.11x

Current Ratio

1.87x

Quick Ratio

1.75x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$1.39

EPS Surprise

−15.76%

Beats (12Q)

4/12

Next Q EPS Est

$1.90

Avg Surprise (4Q)

6.88%

Rev Surprise

7.61%

Financials snapshotView financials →

Revenue (TTM)

3.37B

Net Income (TTM)

705.50M

Op. CF (TTM)

898.10M

Next earningsNov 2, 2026 →

Latest newsMore news →

Neurocrine Biosciences announced that it initiated a Phase 2 clinical study of NBI-1117567 in adults with mild to moderate Alzheimer's disease.5d ago

Neurocrine Biosciences announced new real-world data describing how classic congenital adrenal hyperplasia affects patients’ clinical and day-to-day needs across life stages.9d ago

Similar companies

华润江中600750.SH 海正药业600267.SH 九洲药业603456.SH Grand Pharmaceutical Group Limited00512.HK Sunshine Lake Pharma Co., Ltd.06887.HK 步长制药603858.SH Find similar companies →

Latest newsMore news →

Neurocrine Biosciences announced that it initiated a Phase 2 clinical study of NBI-1117567 in adults with mild to moderate Alzheimer's disease.5d ago Neurocrine Biosciences announced new real-world data describing how classic congenital adrenal hyperplasia affects patients’ clinical and day-to-day needs across life stages.9d ago